Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as ASA404
vadimezan · 2 trials · 2 indications
| Arm | Type | Description |
|---|---|---|
| ASA404 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| vadimezan | DRUG | - |
| ASA404 | DRUG | - |
Inclusion Criteria: 1. Patients with confirmed solid tumors whose disease has progressed or recurred after treatment at lease one therapy, except docetaxel 2. WHO Performance Status of 0-1 Exclusion Criteria: 1. Patients having symptomatic CNS tumor/metastasis and requiring treatment 2. Patients ...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 3 | PHASE2 | Pembrolizumab, Gardasil 9 |
| Incyte Corporation | INCY | 1 | PHASE2 | Retifanlimab |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE1 | KFA115 |
| Iovance Biotherapeutics Inc | IOVA | 2 | PHASE2 | Aldesleukin |
| AstraZeneca PLC | AZN | 1 | - | Trastuzumab deruxtecan |
Vadimezan is an investigational small molecule being studied for the treatment of advanced or recurrent solid tumors. It is an oncology drug candidate developed by Novartis AG. As of the available data, vadimezan is in Phase 1 clinical development and has not been approved by regulatory authorities.
Vadimezan is being developed by Novartis AG, a multinational pharmaceutical company traded on the New York Stock Exchange under the ticker symbol NVS. The drug is an investigational small molecule intended for the treatment of advanced or recurrent solid tumors.
Vadimezan is in Phase 1 clinical development. It is an investigational drug and has not received regulatory approval. The drug is being studied for the treatment of advanced or recurrent solid tumors, and its clinical development is still in the early stages.
Vadimezan has one completed clinical trial registered under NCT01285453, titled "Safety and Tolerability of ASA404 Administered in Combination With Docetaxel in Japanese Patients With Solid Tumors." This Phase 1 study enrolled 9 participants with advanced or recurrent solid tumors in Japan.
Vadimezan is also known as ASA404. The clinical trial NCT01285453 refers to the drug as ASA404, indicating that vadimezan and ASA404 are alternative names for the same investigational compound being developed by Novartis AG.